Avacta Group has filed a patent for therapeutic conjugates with extended circulating serum half-life, linked through a FAPa-cleavable linker. The conjugates have a minimum 48-hour half-life in vivo and do not contain cell-binding moieties with a Kd of 1×10-6 M or less. GlobalData’s report on Avacta Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avacta Group, Laboratory automation robots was a key innovation area identified from patents. Avacta Group's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Extended circulating serum half-life therapeutic conjugates
See Also:
The patent application (Publication Number: US20230390409A1) describes a therapeutic conjugate designed to improve the efficacy of therapeutic moieties by extending their circulating serum half-life in vivo. The conjugate consists of a therapeutic moiety linked through a fibroblast activation protein, alpha (FAPa)-cleavable linker to a half-life extension moiety. Importantly, the conjugate does not contain a cell-binding moiety with a high affinity for cell surface proteins. The half-life extension moiety can include serum proteins like fibronectin, transferrin, or human serum albumin, or molecules that bind to serum proteins, such as antibodies or non-antibody molecules like affibodies or affimers.
Furthermore, the patent application details various formulations and configurations of the therapeutic conjugate, including specific amino acid sequences for the FAPa-cleavable linker, self-immolative linkers, and substrate recognition sequences. The therapeutic moiety can be a cytotoxic, cytostatic, or epigenetic agent, including chemotherapeutic drugs like taxanes or platinum-based agents. The application also covers methods of administering the therapeutic conjugate for treating diseased tissues, particularly cancers, with the aim of increasing efficacy and reducing cytotoxicity. Overall, the patent application outlines a novel approach to enhancing the therapeutic potential of conjugates through targeted delivery and extended half-life in circulation.
To know more about GlobalData’s detailed insights on Avacta Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
